The VxDP is a BMGF initiative that aims to drive advances in vaccine R&D through collaboration with vaccine-pharmaceutical companies, biotechnology institutions, NGOs and academia.
The partnership with GSK will focus on research into vaccine thermostability, with one of the first projects focussed on increasing the heat stability of adjuvants. GSK researchers will look at making AS01, the adjuvant used in GSKâ€™s RTS,S malaria vaccine candidate, more heat stable. â€œReducing the dependence on the cold chain is critical to the affordable delivery of life-saving vaccines to the children who need them most,â€ said Trevor Mundel, president of Global Health at BMGF. GSK and BMGF are to invest a combined $1.8 million in early stage research.
The collaboration between Sanofi Pasteur and BMGF will similarly focus on accelerating vaccine R&D through preclinical and early clinical stages. â€œThese challenging projects would be difficult for any one organization to fund without the Partnership,â€ said John Shiver, Senior VP of R&D for Sanofi Pasteur.â€œThe Gates Foundation is committed to supporting these pilots while we will contribute matching resources and expertise, as well as commit to guaranteeing that advances will support those who need them most through global access provisions.â€
If you want to know more about vaccines, and meet innovators, disruptors and influencers from across the vaccine research, development and technology landscape, find out about the World Vaccine Congress, 24-26 March 2014, Washington DC.